Jade Biosciences, Inc. Debt Securities, Available-for-sale
Jade Biosciences, Inc. (JBIO) had Debt Securities, Available-for-sale of $353.95 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale $353.95M.
- 2026-03-31: Debt Securities, Available-for-sale $256.21M.
- 2025-12-31: Debt Securities, Available-for-sale $247.72M.
- 2025-09-30: Debt Securities, Available-for-sale $148.80M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $353.95M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $256.21M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $247.72M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $148.80M 10-Q · filed 2025-11-14 |
| 2025-03-31 | $31.99M 10-Q · filed 2025-04-25 |
| 2024-12-31 | $44.87M 10-Q · filed 2025-04-25 |
| 2024-09-30 | $57.62M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $73.13M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $90.21M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $98.95M 10-K · filed 2025-03-27 |
| 2023-09-30 | $103.02M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $89.19M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $92.36M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $106.82M 10-K · filed 2024-03-25 |
| 2022-09-30 | $120.16M 10-Q · filed 2022-11-14 |
| 2021-12-31 | $113.18M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |